10-QPeriod: Q1 FY2025

AGILENT TECHNOLOGIES, INC. Quarterly Report for Q1 Ended Jan 31, 2025

Filed March 3, 2025For Securities:A

Summary

Agilent Technologies, Inc. reported total net revenue of $1.681 billion for the third fiscal quarter ended January 31, 2025, a slight increase of 1% compared to the prior year period. This growth was driven by the Life Sciences and Diagnostics Markets segment, which saw a 4% increase, and the Agilent CrossLab segment, which grew by 1%. However, the Applied Markets segment experienced a 4% decline in revenue. Net income for the quarter was $318 million, down from $348 million in the same quarter last year, with diluted earnings per share of $1.11 compared to $1.18 in the prior year. Despite a slight revenue increase, the company saw a decrease in overall profitability and a decline in gross and operating margins. The company also repurchased $90 million of its common stock during the quarter and maintained its quarterly dividend, reflecting a continued commitment to returning capital to shareholders. Agilent's cash position remains strong, with cash and cash equivalents totaling $1.467 billion. The company has reorganized its reporting segments, and management anticipates a steady recovery in customer capital budgets while remaining optimistic about long-term market health.

Financial Highlights

57 data points
Beta

Revenue

$1.68B

53.5% Gross Margin

Net Income

$318.00M

18.9% Net Margin

EPS (Diluted)

$1.11

Total Assets

$11.91B

Cash & Equivalents

$1.47B

Free Cash Flow

$334.00M

Financial Statements
Beta
Revenue$1.68B
Cost of Revenue$782.00M
Gross Profit$899.00M
R&D Expenses$113.00M
SG&A Expenses$410.00M
Operating Expenses$1.30B
Operating Income$376.00M
Interest Expense$28.00M
Net Income$318.00M
EPS (Basic)$1.12
EPS (Diluted)$1.11
Shares Outstanding (Basic)285.00M
Shares Outstanding (Diluted)287.00M

Key Highlights

  • 1Total net revenue increased by 1% year-over-year to $1.681 billion.
  • 2Life Sciences and Diagnostics Markets segment revenue grew by 4%, while Agilent CrossLab grew by 1%.
  • 3Applied Markets segment revenue declined by 4% year-over-year.
  • 4Net income decreased to $318 million from $348 million in the prior year period.
  • 5Diluted earnings per share were $1.11, down from $1.18 in the prior year.
  • 6The company repurchased $90 million of its common stock during the quarter.
  • 7Cash and cash equivalents remained strong at $1.467 billion.

Frequently Asked Questions

Agilent Technologies reported total net revenue of $1.681 billion for the third fiscal quarter ended January 31, 2025, representing a 1% increase compared to the same period last year. Revenue from the Life Sciences and Diagnostics Markets and Agilent CrossLab segments increased, while the Applied Markets segment experienced a decrease.

Net income for the quarter was $318 million, a decrease from $348 million in the prior year's comparable quarter. Diluted earnings per share also decreased to $1.11 from $1.18 year-over-year, indicating a reduction in profitability.

During the three months ended January 31, 2025, Agilent repurchased $90 million of its common stock under its 2023 repurchase program. The company also continued its dividend payments, declaring a quarterly dividend of $0.248 per share.

In November 2024, Agilent announced a restructuring that combines its former Diagnostics and Genomics segment with liquid chromatography and mass spectrometry platforms into a new Life Sciences and Diagnostics Markets segment. The chemistries, supplies, laboratory automation, and software divisions moved to the Agilent CrossLab segment, and the remaining divisions form the new Applied Markets segment. This new structure is reflected in the financial reporting starting this quarter.